Pakistan accuses pharmaceutical companies of malpractice

The Federal Board of Revenue (FBR) in Pakistan believes pharmaceutical companies have used transfer pricing to evade Rp500 million ($5.8 million) in taxes.

Locked content

The article you are trying to view is only available to subscribers and current trialists